Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

文献中の引用(143)

カスタマーフィードバック(21)

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341)は一種の有効な20Sプロテアソーム阻害剤で、Ki値が0.6nMですが、正常細胞より腫瘍細胞に良好な選択性をもっと表します。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MV3DfZRwfG:6aXOgRZN{[Xl? NEPlNI82OCEQvF2= NYjoS2RPPDhiaB?= MXzEUXNQ M{LpPWtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MUSxNFQ6QTZ2Mx?=
OVCA 429 NVvGb2dpTnWwY4Tpc44hSXO|YYm= MlraN|AxKG6P MoPrOFghcA>? M2LzVGROW09? MX\EbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= NUPkZXB{OTB7OUm3OlY>
RPMI8226 NHrMXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDNV|VLOTByIH7N MVm0PEBp NEfMSppFVVOR M4TSPGlEPTB;M{Cgcm0> M1\vU|EyOzB4NEi5
Dox40 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O0PVExOCCwTR?= MoDVOFghcA>? MVfEUXNQ Mo\UTWM2OD12MDDuUS=> MX[xNVMxPjR6OR?=
MR20 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zH[|ExOCCwTR?= NXXUTHRrPDhiaB?= NVruWVlVTE2VTx?= NGnKfG9KSzVyPUKwJI5O NGK3emUyOTNyNkS4PS=>
LR5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HRSlExOCCwTR?= NECzeZI1QCCq NGDPR2VFVVOR M1SwNmlEPTB;MkCgcm0> NVnmNXdnOTF|ME[0PFk>
U266 NHyyeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxNFAhdk1? MWq0PEBp NXfIfW9tTE2VTx?= NFLoZoRKSzVyPUOgcm0> NVTWeYpYOTF|ME[0PFk>
IM-9 NIm0SGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSwcmsyODBibl2= MUe0PEBp MVzEUXNQ NHPic5BKSzVyPU[gcm0> MX[xNVMxPjR6OR?=
Hs Sultan NE\xbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNFAhdk1? MY[0PEBp MX;EUXNQ NVfBWFQyUUN3ME2yNEBvVQ>? M{ixN|EyOzB4NEi5
PAM-LY2 Mm[zSpVv[3Srb36gRZN{[Xl? MlLaNVAxKG6P MkjJNVIhcA>? NYfaR5BqTE2VTx?= MnnCTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= MVuxNVM2ODlzMx?=
PAM 212 NV\1[HFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZZ|lsOTByIH7N M4jCN|czKGh? M1OwXWROW09? NHjBXo5KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NFfM[lEyOTN3MEmxNy=>
PAM-LY2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTnNVAxKG6P MoTyO|IhcA>? MWDEUXNQ NELyTpNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M3;ZN|EyOzVyOUGz
B4B8 M3:3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3mNVAxKG6P Mny1O|IhcA>? NXXKZpRpTE2VTx?= MoTKTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M3\YTFEyOzVyOUGz
B7E3 M4rsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNFAhdk1? MnvwO|IhcA>? MWfEUXNQ MYfJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M{HMNlEyOzVyOUGz
UM-SCC-9 M2r4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPLVplEOTByIH7N NHX0OmE4OiCq MYPEUXNQ MUjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M4PtRVEyOzVyOUGz
UM-SCC-11B NWnyVVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzmWpIyODBibl2= Mkf1O|IhcA>? MUnEUXNQ MUjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NVnXOXVJOTF|NUC5NVM>
H460 MVnGeY5kfGmxbjDBd5NigQ>? Mkf5NVAh|ryP NXTSSHVbOjRiaB?= NEDWRoJFVVOR MVPJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 MmT2NVI1QTJzMUe=
U266 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OwOFUxOCCwZz;tcC=> NELaTnU1QCCq NVz2VGZoTE2VTx?= NV3SZ|FLUW6qaXLpeJMh[2WubDDndo94fGh? M1HMVlEzPjNzNkG5
ARH77 M4K0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrMOVAxKG6pL33s Mn3QOFghcA>? MVzEUXNQ NHX0XVhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NEC3SncyOjZ|MU[xPS=>
WAD-1 NYX5OIZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi1NFAhdmdxbXy= NVXtNmpsPDhiaB?= MUDEUXNQ NIrJe|hKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MnnVNVI3OzF4MUm=
U266/LR7 M3z3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDOOVAxKG6pL33s M3XCbFQ5KGh? MnHvSG1UVw>? MlrPTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MUWxNlY{OTZzOR?=
U266/dox4 M3PVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfRZW81PTByIH7nM41t M{PxblQ5KGh? M1\3fGROW09? MWrJcohq[mm2czDj[YxtKGe{b4f0bC=> NGDJ[|cyOjZ|MU[xPS=>
RPMI8226/LR5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonxOVAxKG6pL33s M4fRZlQ5KGh? NUThdmJTTE2VTx?= M{SybGlvcGmkaYTzJINmdGxiZ4Lve5Rp MoXYNVI3OzF4MUm=
H460 M33wR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNEDPxE1? NFXCUWc4OiCq M2C3TGROW09? MUnJR|UxRTFyMDDuUS=> MV6xNlY{OTZ{MB?=
H358 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNEDPxE1? Mk\vO|IhcA>? Mn\FSG1UVw>? M37wdGlEPTB;N{Cgcm0> MmT5NVI3OzF4MkC=
H322 M13HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxNEDPxE1? NXSyTI1SPzJiaB?= M2Doe2ROW09? NGTMeZZKSzVyPU[yNEBvVQ>? NX3MOpVoOTJ4M{G2NlA>
H460 NULjUmVZTnWwY4Tpc44hSXO|YYm= MnXUNVAxKG6P NXzOPVRvOjRiaB?= M{DRPGROW09? M3G0fmlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? NHP6[G8yOjZ|MU[yNC=>
LNCap-Pro5 Mm\RSpVv[3Srb36gRZN{[Xl? M3TtNVEh|ryP M4LxcVQhcA>? MUTEUXNQ NFfTZ5NUfGGkaXzpfoV{KHB3Mx?= NHm1VYYyPDZzMkWzNi=>
T29 NGTHeWhCeG:ydH;zbZMhSXO|YYm= Mn21OVAhdk1? MVW0PEBpKA>? NEOySlhFVVOR NFHyTopKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkO5NVY4PzhzN{m=
T29Kt1 NYLSR5NKSXCxcITvd4l{KEG|c3H5 M{P3VlUxKG6P NXTSPIdHPDhiaDC= MkHsSG1UVw>? M3jXPWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVGxOlc4QDF5OR?=
HCT116 M4TqSWFxd3C2b4Ppd{BCe3OjeR?= M{LRTFUxKG6P M2jsbFQ5KGhi NIPDRXVFVVOR MUnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVn0PJd2OTZ5N{ixO|k>
HKe-3 NVLMSYE1SXCxcITvd4l{KEG|c3H5 MmrjOVAhdk1? M1PwWFQ5KGhi MkLtSG1UVw>? NULCV3Z6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NI[4XmYyPjd5OEG3PS=>
NB-1691 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;4WGdvOSEQvF2= NGjybHk4OiCq MXzJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? Mn33NVc3QDl4OES=
CHLA-255 M1XpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5[HUyKM7:TR?= NHHiRpE4OiCq NGfTTW1KdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NYH5[I9xOTd4OEm2PFQ>
SK-N-AS NV\JdWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxJO69VQ>? MXW3NkBp M{H5WGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= NHzJTm0yPzZ6OU[4OC=>
NB-1691 M3nDWGZ2dmO2aX;uJGF{e2G7 NX7iWXFJOTBibl2= NH3RV5AzPCCq MXfTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl NVnLN25wOTd4OEm2PFQ>
CHLA-255 M{T0Z2Z2dmO2aX;uJGF{e2G7 MXGxNEBvVQ>? MoXINlQhcA>? NFjF[m1Od2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= M{HhV|E4Pjh7Nki0
RPMI 8226 NIOybYJHfW6ldHnvckBCe3OjeR?= MniwNlAhdk1? NEXvNG45KGh? MmPlV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NWHo[4dCOTl2M{[wOVA>
MM.1S MVTGeY5kfGmxbjDBd5NigQ>? NYrMelhLOjBibl2= Ml7HPEBp M3njUnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NH;PTpAyQTR|NkC1NC=>
U266 MoDjSpVv[3Srb36gRZN{[Xl? NHmzVYwzOCCwTR?= MlnvPEBp NHHtd5NUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M{fTV|E6PDN4MEWw
OPM1 MV;GeY5kfGmxbjDBd5NigQ>? M1W1TFIxKG6P NGrsZ|U5KGh? MWHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M3rFcVE6PDN4MEWw
INA6 MlPJSpVv[3Srb36gRZN{[Xl? M2TLe|IxKG6P NGDJVHo5KGh? M2XhWXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NYPWSWZ1OTl2M{[wOVA>
OPM2 M2TNOWZ2dmO2aX;uJGF{e2G7 NUjT[nFqOjBibl2= NVv5R3o1QCCq MUjTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MWqxPVQ{PjB3MB?=
RPMI 8226 MXXGeY5kfGmxbjDBd5NigQ>? Mke1NlAhdk1? MoHzPEBp MV;JcoR2[2W|IFTORUB{gW62aHXzbZM> M4DDe|E6PDN4MEWw
BaF/3 NGnjW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnLSWcyODBibl2= NFLNNW81QCCq MYjJR|UxRTZwMjDuUS=> MoKzNlA{ODV4OUK=
BaF/3-p210 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TlR|ExOCCwTR?= NXzLcpJyPDhiaB?= NFL3TJRKSzVyPUSuO{BvVQ>? MkDUNlA{ODV4OUK=
TCC-S NImzNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6dHF[OTByIH7N MVq0PEBp MmD2TWM2OD1{Lkigcm0> NI\CW|czODNyNU[5Ni=>
BaF/3 NIHzT2VHfW6ldHnvckBCe3OjeR?= M4HoWlYhdk1? Mn;vOFghcA>? NVu5O5hPUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MXKyNFMxPTZ7Mh?=
BaF/3-p210 MmHVSpVv[3Srb36gRZN{[Xl? Mnf5OkBvVQ>? M4XEVlQ5KGh? M4nUXWlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> M{WzS|IxOzB3Nkmy
BaF/3-p210 NWHVUoU5TnWwY4Tpc44hSXO|YYm= NVzvXohRPiCwTR?= NVTEco8zOjRiaB?= NWTsR5dxWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= NHPN[nEzODNyNU[5Ni=>
Raji NUPne2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjvWFAxOSEQvF2= Mlv2NlQhcA>? NHXRXnRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkfZNlEyPzB7OEi=
LCL-1 NHTKdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGxJO69VQ>? NHHFfWEzPCCq NHHOWI1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnfzNlEyPzB7OEi=
LCL-2 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxJO69VQ>? MoPTNlQhcA>? NGO2UHNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NHvqb4YzOTF5MEm4PC=>
BJAB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\1N|Eh|ryP MknnNlQhcA>? NUDJW|Q5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NW\vR|dQOjFzN{C5PFg>
SNT-13 M4LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X1b|Eh|ryP MXSyOEBp MkPkVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MYSyNVE4ODl6OB?=
SNT-16 NVjjO21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17lO|Eh|ryP NX\DS2o{OjRiaB?= NES1ZlJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVqyNVE4ODl6OB?=
Jurkat NVPoZZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxJO69VQ>? NV;mOnJuOjRiaB?= NHzTeY9T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M{\3WFIyOTdyOUi4
KAI-3 M3XFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzaWZkyKM7:TR?= NIrNWmczPCCq MXLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M3L5Z|IyOTdyOUi4
SNK-6 NWLjc|ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xJO69VQ>? MlzMNlQhcA>? MkfPVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MnXvNlEyPzB7OEi=
KHYG-1 M4DxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2NUDPxE1? M3Ppe|I1KGh? Ml3XVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M330PFIyOTdyOUi4
SNT-16 NE\3b3BCeG:ydH;zbZMhSXO|YYm= NWPGS5JoOSEQvF2= MW[2JIg> M4e4Smlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NV;iV4tkOjFzN{C5PFg>
Jurkat MUHBdI9xfG:|aYOgRZN{[Xl? NHrNSo0yKM7:TR?= MnXLOkBp M4W1d2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWSyNVE4ODl6OB?=
KAI-3 M2XVc2Fxd3C2b4Ppd{BCe3OjeR?= MUCxJO69VQ>? M1TvW|YhcA>? M2\Ffmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{n1PFIyOTdyOUi4
KHYG-1 MlnuRZBweHSxc3nzJGF{e2G7 NIDtZ|kyKM7:TR?= M1jDNFYhcA>? NWjtTZg5UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYX4T3BDOjFzN{C5PFg>
SNT-13 M1X5TGFvfGm4aYLhcEBCe3OjeR?= NG\lbIEyKM7:TR?= MWWyOEBp M162W2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? Ml;jNlEyPzB7OEi=
SNT-16 NETQWVhCdnSrdnnyZYwhSXO|YYm= M3X0U|Eh|ryP M13DOVI1KGh? NX[2cHF1UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MYiyNVE4ODl6OB?=
KAI-3 NVvXV2RHSW62aY\pdoFtKEG|c3H5 MoXtNUDPxE1? NVvke3N2OjRiaB?= M{DMTWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NHzydIozOTF5MEm4PC=>
SNK-6 NHPmdVdCdnSrdnnyZYwhSXO|YYm= NV;yZ2dmOSEQvF2= NG\wVWMzPCCq MWXJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NGDSZpczOTF5MEm4PC=>
RAW 264.7 M32xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4V|ExOCCwTR?= MlXFOFghcA>? M33Nb3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NWK4cll4OjJ2MkexOVQ>
A375 M2\5emFxd3C2b4Ppd{BCe3OjeR?= Ml[xNVAhdk1? MnTrNlQhcA>? Mmj0TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlnVNlMxPzlyOEO=
BLM NXXaTIx1SXCxcITvd4l{KEG|c3H5 NUH2[HNKOTBibl2= NXnPZmRFOjRiaB?= MU\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlnnNlMxPzlyOEO=
A375 MoXBRZV1d3CqYXf5JGF{e2G7 M1HVeVExKG6P NFL4b5IyOiCq NVy3VYpXUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> M2rkUlI{ODd7MEiz
BLM NGDyNmRCfXSxcHjh[5khSXO|YYm= NELVOogyOCCwTR?= MnGzNVIhcA>? M2rZVmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M2fQ[|I{ODd7MEiz
H1299 M1;VOGFxd3C2b4Ppd{BCe3OjeR?= NHn4RYY5OCCwTR?= M2DtVFI1KGh? NXnRbHdGTE2VTx?= NF3VXmFU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= NHrtZW0zPTN{M{[5Ny=>
Hut-78 NG\xWJhHfW6ldHnvckBCe3OjeR?= Mon5NVAxKG6P NUXsNWxIOjRiaB?= M4q4OGROW09? NV35c3dzTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u MkPRNlU3QDF|M{W=
H9 MXLGeY5kfGmxbjDBd5NigQ>? M3jXbFExOCCwTR?= NUXvNJN1OjRiaB?= MmD2SG1UVw>? MnO4SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w NGixb3UzPTZ6MUOzOS=>
HH M4nacmZ2dmO2aX;uJGF{e2G7 NF\TbXQyODBibl2= M2nJ[FI1KGh? NH72dWhFVVOR NHruNodld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36= NVK3b2kzOjV4OEGzN|U>
Hut-78 MVTNbYdz[XSrb36gRZN{[Xl? MUKxNFAhdk1? NFXRPFQzPCCq NUm5fJJkTE2VTx?= MXTS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn M{fW[lI2PjhzM{O1
HH NYTnO3lVVWmpcnH0bY9vKEG|c3H5 NVjy[nJlOTByIH7N MlXyNlQhcA>? NIPIZ2NFVVOR M2PI[nJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= M4XwOFI2PjhzM{O1
U937 M3PrZmZ2dmO2aX;uJGF{e2G7 MVKxNFAhdk1? MnvkOkBp NXzpXodoUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= MlvhNlU4QTF2N{e=
human PBMC M2qxcWZ2dmO2aX;uJGF{e2G7 NVH3cYY{OTByIH7N MljwNlQhcA>? MV3JcoR2[2W|IFnMMVghemWuZXHz[S=> NUXGbJNqOjV5OUG0O|c>
ES6 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq0RZZmUUN3ME2wMlAxOjFibl2= M2jYSXNCVkeHUh?=
SK-UT-1 M2PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TvNmlEPTB;MD6xOlMhdk1? NXzDfIlHW0GQR1XS
SH-4 NXfVTVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljITWM2OD1yLkG3N{BvVQ>? MWHTRW5ITVJ?
TE-9 NXvjXmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfp[YlJUUN3ME2wMlE5OiCwTR?= MUPTRW5ITVJ?
A253 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLbGlEPTB;MD6yNFghdk1? M2XrO3NCVkeHUh?=
no-10 M{jCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMkGgcm0> NVv0bW5mW0GQR1XS
MMAC-SF NXGxVWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HReGlEPTB;MD6yNVYhdk1? MVTTRW5ITVJ?
A101D MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMkK1JI5O MUfTRW5ITVJ?
NTERA-S-cl-D1 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n6PGlEPTB;MD6yOFMhdk1? NGryZXlUSU6JRWK=
8-MG-BA NV3pWZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMkWgcm0> NWG3XZBuW0GQR1XS
KNS-42 NVnuR|NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jcnlKSzVyPUCuNlU5KG6P MonzV2FPT0WU
LXF-289 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWOGRvUUN3ME2wMlI3QSCwTR?= NYLaR3ZOW0GQR1XS
OVCAR-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnkVXMyUUN3ME2wMlI5QSCwTR?= MnrjV2FPT0WU
LOUCY MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkmzJI5O M2DtNnNCVkeHUh?=
BB65-RCC M{iwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X2T2lEPTB;MD6zNFQhdk1? NXvrWWtFW0GQR1XS
D-542MG NIrLWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe5b|BKSzVyPUCuN|I6KG6P M3LOWnNCVkeHUh?=
ONS-76 NIrqOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[3[WpKSzVyPUCuN|Mhdk1? M2DKR3NCVkeHUh?=
BB30-HNC M2XJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTzfHFrUUN3ME2wMlM{PSCwTR?= NV7HZ5g1W0GQR1XS
KS-1 NWXmNGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1yLkO0JI5O NUO4TWxlW0GQR1XS
A388 NWDJOoFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzVTWM2OD1yLkO1OkBvVQ>? MoP6V2FPT0WU
ES8 NUTrVGdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jvVmlEPTB;MD60JI5O MUfTRW5ITVJ?
MZ2-MEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTndmIzUUN3ME2wMlQxPyCwTR?= NE\q[2NUSU6JRWK=
HCC2998 NXX6W2hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNEGyJI5O MXzTRW5ITVJ?
D-247MG NXewTZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNEGzJI5O NYD4[mVqW0GQR1XS
ACN Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hXlByUUN3ME2wMlQyPyCwTR?= M1\qPHNCVkeHUh?=
LB2518-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHOV2NKSzVyPUCuOFI2KG6P NIfPT3pUSU6JRWK=
ES1 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vw[WlEPTB;MD60N{BvVQ>? NUfhTINVW0GQR1XS
HCE-T MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\VNm1KSzVyPUCuOFM6KG6P M1u4OnNCVkeHUh?=
OS-RC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnBRWdqUUN3ME2wMlQ1KG6P MlP2V2FPT0WU
MFH-ino NVS5NXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNESzJI5O M{TOR3NCVkeHUh?=
OCUB-M M2D2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjwclBKSzVyPUCuOFQ4KG6P MUHTRW5ITVJ?
CP66-MEL M4XSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGeyflhKSzVyPUCuOFc{KG6P MlG5V2FPT0WU
LB771-HNC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwNEe0JI5O MXHTRW5ITVJ?
DSH1 NWXDNWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHpPJdKSzVyPUCuOFghdk1? MoDpV2FPT0WU
HUTU-80 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT6TWM2OD1yLkWzN{BvVQ>? NHvybW9USU6JRWK=
CESS Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qz[2lEPTB;MD61N|ghdk1? M{\vNHNCVkeHUh?=
NCI-H747 M4TEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7kTmZKSzVyPUCuOVM6KG6P NXj4SnNTW0GQR1XS
HT-144 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5NWlEPTB;MD61O|Yhdk1? M3[0[3NCVkeHUh?=
COLO-829 NFH1fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPQRVFKSzVyPUCuOlE1KG6P MWjTRW5ITVJ?
A4-Fuk NFrXcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNkKzJI5O NWrWPIJJW0GQR1XS
GI-ME-N MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\TVZk6UUN3ME2wMlY{PCCwTR?= NV\PXll1W0GQR1XS
LB831-BLC M2fHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNkSxJI5O M2\Ye3NCVkeHUh?=
HOP-62 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwNkS3JI5O MWHTRW5ITVJ?
BB49-HNC M3O2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TDUGlEPTB;MD62OVIhdk1? NH:ybnVUSU6JRWK=
D-336MG NYX3[pRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPrVmJKSzVyPUCuOlU4KG6P M3jtXXNCVkeHUh?=
TK10 NVHWN4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXTWM2OD1yLk[3PUBvVQ>? NV;zcJh2W0GQR1XS
Ramos-2G6-4C10 M1P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofZTWM2OD1yLk[5N{BvVQ>? NWrkRVluW0GQR1XS
LB373-MEL-D M{PLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjSbmF4UUN3ME2wMlchdk1? Mm\VV2FPT0WU
SF126 NWjLc4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\i[YtDUUN3ME2wMlcxOSCwTR?= MYPTRW5ITVJ?
UACC-257 M4GyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTzTolNUUN3ME2wMlcyKG6P NWnZVlhEW0GQR1XS
KINGS-1 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe2SGZRUUN3ME2wMlczOiCwTR?= M3jlOHNCVkeHUh?=
LS-513 M2Hmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfrTWM2OD1yLkezPUBvVQ>? NVHqTm5kW0GQR1XS
GI-1 M4PpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvnTIJzUUN3ME2wMlc3PCCwTR?= M{XCXnNCVkeHUh?=
ES7 M1TYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLteIhNUUN3ME2wMlc3PiCwTR?= NGjRW41USU6JRWK=
LB2241-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnflTWM2OD1yLkiwOEBvVQ>? MlK3V2FPT0WU
D-263MG NVHCOmpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\HSoNKSzVyPUCuPFA4KG6P M4DEOXNCVkeHUh?=
SW684 NX:1fW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwOEKxJI5O MYDTRW5ITVJ?
ML-2 M4XPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDUOFJtUUN3ME2wMlgzOSCwTR?= NYfie3hlW0GQR1XS
SK-LMS-1 M4K3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\qNWlEPTB;MD64OVQhdk1? MVvTRW5ITVJ?
TE-5 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fs[WlEPTB;MD64OlUhdk1? M2\TNXNCVkeHUh?=
QIMR-WIL MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn2TWM2OD1yLki4PUBvVQ>? MkmzV2FPT0WU
NCI-H1355 NYfhT4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P2cmlEPTB;MD64PVUhdk1? NFjSUmVUSU6JRWK=
SNB75 M2HLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4d4liUUN3ME2wMlkyOiCwTR?= NE[1O4JUSU6JRWK=
RXF393 NIf4dGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HrSmlEPTB;MD65NVQhdk1? NVvuT|lGW0GQR1XS
IST-MEL1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nIbmlEPTB;MD65NVchdk1? MV3TRW5ITVJ?
SF268 NUTYfY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnP[48xUUN3ME2wMlkzOyCwTR?= MlTKV2FPT0WU
KALS-1 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\MOm5KSzVyPUCuPVI2KG6P MkCzV2FPT0WU
HC-1 NVLkW|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwOUe1JI5O NHzTVHBUSU6JRWK=
SW872 M2DKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLBTWM2OD1yLkm5OkBvVQ>? MkHuV2FPT0WU
PSN1 M4Lwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DrPGlEPTB;MT6wNUBvVQ>? M{L2fnNCVkeHUh?=
TE-1 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHtOVlKSzVyPUGuNFMhdk1? NVvXXoxJW0GQR1XS
TE-10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwMEOgcm0> NI[4PGRUSU6JRWK=
RKO NITHNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwME[gcm0> NX;1cplbW0GQR1XS
LC-2-ad NXHoPI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwMEigcm0> MVXTRW5ITVJ?
SK-MM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMEmgcm0> MnrCV2FPT0WU
VA-ES-BJ MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLjRWhlUUN3ME2xMlA6KG6P MnX3V2FPT0WU
MZ7-mel M1i3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fFe2lEPTB;MT6wPUBvVQ>? M33yXnNCVkeHUh?=
D-392MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHhPHU4UUN3ME2xMlEhdk1? M13LbHNCVkeHUh?=
CCRF-CEM M33ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[1ZWlEPTB;MT6xN{BvVQ>? M{\pXnNCVkeHUh?=
EM-2 NEmwOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3ZpVKSzVyPUGuNVYhdk1? NFTzb21USU6JRWK=
HAL-01 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfrOGNKSzVyPUGuNVghdk1? NEHtdlNUSU6JRWK=
TE-8 M4rMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLLTWM2OD1zLkG5JI5O NWe3O|I6W0GQR1XS
NCI-H1882 NYXBRohDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHzZnBiUUN3ME2xMlIhdk1? M{DzfnNCVkeHUh?=
Daudi MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwMkKgcm0> MmmxV2FPT0WU
BL-41 NGL0WnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4ZmZ2UUN3ME2xMlI2KG6P M1SxTXNCVkeHUh?=
SR NYPXdJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TZbWlEPTB;MT6yOUBvVQ>? NGXme5NUSU6JRWK=
KM12 NYPnb|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXtPWRKSzVyPUGuNlchdk1? NF7wdVBUSU6JRWK=
K5 NGPPRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDRTlB6UUN3ME2xMlI5KG6P NILJfHhUSU6JRWK=
A3-KAW Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jKSmlEPTB;MT6yPEBvVQ>? NIP5TlNUSU6JRWK=
CMK NX3reZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIVWM4UUN3ME2xMlI6KG6P MWLTRW5ITVJ?
Calu-6 M37PPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn2OpVKSzVyPUGuNlkhdk1? M1m5Z3NCVkeHUh?=
IST-SL2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X2NGlEPTB;MT6zNUBvVQ>? M2\yUHNCVkeHUh?=
OPM-2 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jwUWlEPTB;MT6zN{BvVQ>? MlzZV2FPT0WU
DU-4475 NWnO[oUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjVPVdqUUN3ME2xMlM3KG6P MXfTRW5ITVJ?
ECC12 MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHlemxKSzVyPUGuN|chdk1? MmrvV2FPT0WU
L-540 NXT3NG5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwM{egcm0> MlvIV2FPT0WU
CAS-1 M{nQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXRR482UUN3ME2xMlM4KG6P NF\tWZpUSU6JRWK=
PF-382 NYr4RYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfwXpJKSzVyPUGuOFchdk1? MX7TRW5ITVJ?
LS-411N NX\ZTpdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLZdmNKSzVyPUGuOVMhdk1? M3TSdnNCVkeHUh?=
NCI-H69 M17HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GyfWlEPTB;MT61OEBvVQ>? NVfhTYJnW0GQR1XS
NB12 M1f6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzhWYZKSzVyPUGuOVYhdk1? NFvWUVNUSU6JRWK=
HEL MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TSdWlEPTB;MT62NUBvVQ>? Mlv2V2FPT0WU
GCIY M2\ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonLTWM2OD1zLk[yJI5O M3fXcXNCVkeHUh?=
EHEB NYH4e4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwNkegcm0> MknMV2FPT0WU
TGBC1TKB MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jDfmlEPTB;MT63NUBvVQ>? MVfTRW5ITVJ?
KURAMOCHI MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLTWM2OD1zLkeyJI5O NYrFUJd5W0GQR1XS
U-266 M3m0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPETWM2OD1zLke2JI5O MUHTRW5ITVJ?
LC4-1 M1O1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFb49KSzVyPUGuO|khdk1? MXnTRW5ITVJ?
NCI-H2126 NVizPZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULtbXNKUUN3ME2xMlghdk1? NFPlc29USU6JRWK=
NCI-H1092 NWnF[opWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTZPYw2UUN3ME2xMlghdk1? NWjpVHBuW0GQR1XS
GB-1 NUflPIl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwOEGgcm0> Mo\FV2FPT0WU
MV-4-11 NIHXZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXrdY5ZUUN3ME2xMlgzKG6P M{O2TXNCVkeHUh?=
Becker MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG0OW9vUUN3ME2xMlg{KG6P NYTqcGp7W0GQR1XS
MPP-89 M1T1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDJTWM2OD1zLki5JI5O MV3TRW5ITVJ?
BE-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwOUOgcm0> MlzFV2FPT0WU
697 NEXpUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzkSJJEUUN3ME2xMlk6KG6P NWLoSmw1W0GQR1XS
NKM-1 NGnI[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTvTWtyUUN3ME2yJI5O MUDTRW5ITVJ?
NB13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJibl2= NF;BWXpUSU6JRWK=
LS-123 NX3l[WFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjLTGpFUUN3ME2yMlAzKG6P NGLy[21USU6JRWK=
NB17 M1n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTuTWM2OD1{LkC0JI5O NV2wfpE2W0GQR1XS
LAN-6 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPYdG9KSzVyPUKuNFUhdk1? NXWySoJUW0GQR1XS
EW-24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO3dW5QUUN3ME2yMlA5KG6P NYq4RpNrW0GQR1XS
NOS-1 M2D6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[wfohKSzVyPUKuNVEhdk1? NUP4OIZ6W0GQR1XS
BL-70 NVrRfFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfleVlKSzVyPUKuNVIhdk1? M1jST3NCVkeHUh?=
GT3TKB Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnrTWM2OD1{LkGyJI5O MV\TRW5ITVJ?
HH NXu2cZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6V2lEPTB;Mj6xN{BvVQ>? NYqxOo9NW0GQR1XS
KE-37 NEji[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwMUOgcm0> NVz5[pdjW0GQR1XS
MOLT-4 NICzWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f6dWlEPTB;Mj6xN{BvVQ>? MUjTRW5ITVJ?
EKVX MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLhV|NKSzVyPUKuNVQhdk1? NH3pOo5USU6JRWK=
KGN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzZNWl6UUN3ME2yMlE2KG6P MVPTRW5ITVJ?
ES4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJwMU[gcm0> MV;TRW5ITVJ?
SJSA-1 NH63[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwMkGgcm0> MX\TRW5ITVJ?
KMOE-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDXVpBKSzVyPUKuNlMhdk1? MnLwV2FPT0WU
NB5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISybYVKSzVyPUKuNlchdk1? NH3xOmNUSU6JRWK=
BC-1 M{H6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEexOWNKSzVyPUKuN|Ehdk1? M{LQWnNCVkeHUh?=
NB10 M4fZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\GXGlEPTB;Mj6zNkBvVQ>? Ml7BV2FPT0WU
RPMI-8226 NWW0doJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTEPFdSUUN3ME2yMlM2KG6P MojLV2FPT0WU
SCC-3 NWn2TIhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u3VWlEPTB;Mj6zO{BvVQ>? NVj5S2JDW0GQR1XS
ARH-77 NUX4RYd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW1bJpKSzVyPUKuN|ghdk1? NWG5eWZmW0GQR1XS
NCI-H748 NWHK[VNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPSe49VUUN3ME2yMlM6KG6P MnjRV2FPT0WU
KU812 NHLB[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm4TWM2OD1{LkSyJI5O NYjrO3JGW0GQR1XS
NCI-H64 NHL6NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPL[21KSzVyPUKuOFQhdk1? M4TqUXNCVkeHUh?=
NB69 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS5PVRCUUN3ME2yMlQ3KG6P NHjDOoxUSU6JRWK=
KNS-81-FD M2HTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W0WGlEPTB;Mj60PEBvVQ>? MVHTRW5ITVJ?
LB1047-RCC MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwNUegcm0> NFTEOGlUSU6JRWK=
EB-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWxTWM2OD1{Lk[2JI5O MoPDV2FPT0WU
Mo-T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TYTGlEPTB;Mj63OEBvVQ>? M1y2e3NCVkeHUh?=
EW-16 M2XwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL2N3BQUUN3ME2yMlc2KG6P M{PvWnNCVkeHUh?=
CTV-1 NU\kUlhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwODDuUS=> NFPSbWNUSU6JRWK=
ETK-1 M3jPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP4[GlKSzVyPUKuPFQhdk1? M{nPbHNCVkeHUh?=
C2BBe1 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwOEmgcm0> NHzScmZUSU6JRWK=
MOLT-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[0ZmlEPTB;Mj64PUBvVQ>? MWHTRW5ITVJ?
SW954 NGL2dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn73TWM2OD1{Lkmgcm0> MnjuV2FPT0WU
HT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNwMEKgcm0> M3\kPHNCVkeHUh?=
KARPAS-299 NFHG[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwME[gcm0> MWXTRW5ITVJ?
MONO-MAC-6 NWDPfYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3R5djUUN3ME2zMlEhdk1? M3ewW3NCVkeHUh?=
CGTH-W-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DWfWlEPTB;Mz6xJI5O NIrqZZhUSU6JRWK=
SK-PN-DW NYnaPY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP5TWM2OD1|LkG0JI5O NGnaT2NUSU6JRWK=
CW-2 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwMkGgcm0> MlrLV2FPT0WU
SK-N-DZ MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvxTWM2OD1|LkK2JI5O MWPTRW5ITVJ?
NEC8 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3MTWM2OD1|LkO1JI5O NH;meZJUSU6JRWK=
LB996-RCC MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G3OGlEPTB;Mz60JI5O NYfoNHJCW0GQR1XS
DB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fET2lEPTB;Mz60NUBvVQ>? M3nZPHNCVkeHUh?=
TE-15 NY\acXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jCZWlEPTB;Mz60N{BvVQ>? NWrmU3J{W0GQR1XS
COR-L88 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH0TVNKSzVyPUOuOFchdk1? MYfTRW5ITVJ?
LAMA-84 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTwTWM2OD1|LkS5JI5O M4O3N3NCVkeHUh?=
MEG-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPSWmJKSzVyPUOuOFkhdk1? MX7TRW5ITVJ?
LOXIMVI NV;ZUGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvuW|ZEUUN3ME2zMlUhdk1? NF23OnFUSU6JRWK=
RPMI-8402 NXrGZ|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwNTDuUS=> MkP2V2FPT0WU
KARPAS-45 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCVWoyUUN3ME2zMlU1KG6P NHr6b5BUSU6JRWK=
HCC1187 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnKVJFCUUN3ME2zMlU1KG6P MYTTRW5ITVJ?
MZ1-PC MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNUSgcm0> NWXCfosyW0GQR1XS
no-11 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILRWZJKSzVyPUOuOVUhdk1? MoXFV2FPT0WU
EVSA-T MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHqTWM2OD1|Lk[gcm0> Mn3IV2FPT0WU
DJM-1 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPKd4tKSzVyPUOuOlMhdk1? MonKV2FPT0WU
COLO-684 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[1OmlEPTB;Mz62OkBvVQ>? NFj0PZFUSU6JRWK=
NMC-G1 NYXh[GxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvHdYZKSzVyPUOuOlghdk1? MmXEV2FPT0WU
LC-1F NUP0eIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOze5ZKSzVyPUOuO|Qhdk1? M2TLeHNCVkeHUh?=
RL95-2 NUnHXIVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnqTWM2OD1|Lke5JI5O MmDFV2FPT0WU
COLO-320-HSR NXL0V2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwOUKgcm0> M3jzUnNCVkeHUh?=
RCC10RGB NWKwW203T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPGcoRCUUN3ME2zMlk{KG6P MomyV2FPT0WU
HD-MY-Z M3fmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS0R5Z5UUN3ME2zMlk{KG6P NIj1S3hUSU6JRWK=
NCI-H2141 NWXwdHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz2SIRKSzVyPUSuNFUhdk1? NVTQcZYxW0GQR1XS
K-562 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjFdpk1UUN3ME20MlEzKG6P NUXhNYZoW0GQR1XS
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT6dGF{UUN3ME20MlE{KG6P M13CeXNCVkeHUh?=
OMC-1 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfPV2s1UUN3ME20MlE5KG6P NYjRZ5dzW0GQR1XS
LB647-SCLC MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL0RW9KUUN3ME20MlIzKG6P M{O3OnNCVkeHUh?=
TE-12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHJTWM2OD12LkK1JI5O M4HQ[3NCVkeHUh?=
NOMO-1 M{LnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ydmpKSzVyPUSuN|Mhdk1? M{[yU3NCVkeHUh?=
Raji MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzjUVQ3UUN3ME20MlQ3KG6P MnvZV2FPT0WU
NALM-6 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXtOYtKSzVyPUSuOFkhdk1? MnHtV2FPT0WU
HL-60 M{\Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TwPGlEPTB;ND62O{BvVQ>? MUjTRW5ITVJ?
IST-SL1 NF61PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTRwNkigcm0> NXfqbGFbW0GQR1XS
MHH-PREB-1 NHrHd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmxRnE3UUN3ME20Mlg3KG6P MX;TRW5ITVJ?
MHH-NB-11 NXPVR3h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16ySmlEPTB;ND65NUBvVQ>? MlK1V2FPT0WU
JiyoyeP-2003 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zTfWlEPTB;NTDuUS=> Mof2V2FPT0WU
SBC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDzW5FTUUN3ME21MlAyKG6P NFjSbpVUSU6JRWK=
CHP-126 NVHNbYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzuTWM2OD13LkC2JI5O M1HGUHNCVkeHUh?=
LU-139 NH:5RmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCbZdKSzVyPUWuNVMhdk1? M{TBdXNCVkeHUh?=
NCI-SNU-5 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTVwMUegcm0> MUXTRW5ITVJ?
SW962 NWfEcohNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTVwMkGgcm0> M{PoWnNCVkeHUh?=
EW-1 NEPaSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfTeJdKSzVyPUWuN|Ehdk1? NGThW2dUSU6JRWK=
NCI-H1417 NHewdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwNUGgcm0> NYrYUXNtW0GQR1XS
LU-65 M{L5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q4XGlEPTB;NT64OEBvVQ>? M13t[3NCVkeHUh?=
D-502MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXzcpFKSzVyPU[uN|chdk1? NXTydpJ2W0GQR1XS
BC-3 NUmyTm9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD14Lk[xJI5O NX:zcmhqW0GQR1XS
GDM-1 NIrMcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTZwN{egcm0> M1HreHNCVkeHUh?=
NCI-H2196 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XodWlEPTB;Nj64JI5O MYTTRW5ITVJ?
NB1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S2PWlEPTB;Nj64PEBvVQ>? MVPTRW5ITVJ?
NCI-H345 NUmyVXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\WZplKSzVyPUeuNkBvVQ>? MYrTRW5ITVJ?
SU-DHL-1 M2XSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\2NJNJUUN3ME23MlI1KG6P MUnTRW5ITVJ?
JVM-2 NHvnbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTdwMkigcm0> NXPIUppQW0GQR1XS
LU-134-A NWjDfZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwM{mgcm0> M2TTdHNCVkeHUh?=
NCI-H1694 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTU3lpUUN3ME23MlU5KG6P NFfFfY1USU6JRWK=
NCI-SNU-16 NX;rRWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG1[4RKSzVyPUeuOlUhdk1? MkfWV2FPT0WU
L-363 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\mTGlEPTB;Nz63JI5O NX;2UWdwW0GQR1XS
KG-1 NX65elBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DPVGlEPTB;Nz65OEBvVQ>? NV30fpM5W0GQR1XS
MN-60 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe2ZZhKSzVyPUiuNVQhdk1? MorqV2FPT0WU
NB6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPOTWM2OD16LkS4JI5O NHTGbnpUSU6JRWK=
MLMA NHj3SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16w[WlEPTB;OD64OUBvVQ>? MkLzV2FPT0WU
ATN-1 M2HZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;KfYV5UUN3ME24Mlg6KG6P M3OxcnNCVkeHUh?=
SK-NEP-1 NFfT[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K2bGlEPTB;OT6wNUBvVQ>? NYjOXHR[W0GQR1XS
DMS-114 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13m[WlEPTB;OT62NkBvVQ>? NHnmOWtUSU6JRWK=
CTB-1 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwNkegcm0> M1;xWXNCVkeHUh?=
NCI-H2081 M4CyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\hTWM2OD1zMD6wPUBvVQ>? NFTYPZFUSU6JRWK=
ES5 NVexcmg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFyLkO4JI5O NWSxV|dnW0GQR1XS
HCC1599 NWnxfnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHySJRKSzVyPUGxMlkyKG6P NWPjW3hRW0GQR1XS
NCI-H23 NUDpT2J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXrUoVZUUN3ME2xNk4yOiCwTR?= NXTBSXlRW0GQR1XS
NCI-H1581 NF3FO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\i[WRoUUN3ME2xNk4zQCCwTR?= NEC3fFFUSU6JRWK=
JVM-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF{Lkm5JI5O NHXLc|lUSU6JRWK=
NCI-SNU-1 NUCxfZlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LobGlEPTB;MUOuNVkhdk1? NGTRdpZUSU6JRWK=
NB7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7iTWM2OD1zNT65NkBvVQ>? NYDjSJU1W0GQR1XS
JAR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF4LkGzJI5O NIHFZYlUSU6JRWK=
TGW NILYO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Kc4RKSzVyPUG2MlQ5KG6P MX\TRW5ITVJ?
U-87-MG MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1zNj63OkBvVQ>? Mnf0V2FPT0WU
NCI-H1436 NW\LNmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nyRWlEPTB;MUeuNFEhdk1? NI[0N5FUSU6JRWK=
GOTO M3f1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrIN2ZKSzVyPUG3MlA3KG6P NEjmblhUSU6JRWK=
COLO-800 M4PWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID3R2hKSzVyPUG3MlY1KG6P MYLTRW5ITVJ?
MFM-223 NF;6UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPZTWM2OD1zNz65NUBvVQ>? MmjMV2FPT0WU
EW-18 NWL3fGlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HicGlEPTB;MUeuPVYhdk1? MYTTRW5ITVJ?
NB14 NWfodpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\oTWM2OD1zNz65PEBvVQ>? M3vVUXNCVkeHUh?=
EB2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfyZllKSzVyPUG4MlA5KG6P MW\TRW5ITVJ?
EoL-1- NVnQXJl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrBfZpKSzVyPUG4MlMyKG6P MXXTRW5ITVJ?
NCCIT NF[2bmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PFO2lEPTB;MUiuN|Yhdk1? NIXEb5RUSU6JRWK=
DG-75 NUCyZWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzLNm1KSzVyPUG4MlYyKG6P NG\QV|dUSU6JRWK=
HCC2218 NVnucVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL3dJFKSzVyPUG5MlUhdk1? NVjJZmV6W0GQR1XS
TE-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJyLkC4JI5O MUjTRW5ITVJ?
SF539 M2TsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ZVm51UUN3ME2yNE43PyCwTR?= M17VOnNCVkeHUh?=
NCI-H446 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHtNnVXUUN3ME2yNU4yQCCwTR?= M3KwRXNCVkeHUh?=
IST-MES1 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOyTpBKSzVyPUKyMlc4KG6P Mn3HV2FPT0WU
NCI-H82 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Z[WlEPTB;MkOuNFIhdk1? Mk[3V2FPT0WU
HCC2157 NGnncnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XUOWlEPTB;MkOuNVMhdk1? MlfxV2FPT0WU
EW-12 M1e5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W5d2lEPTB;MkOuNVchdk1? MlXCV2FPT0WU
SIMA NF6yfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ|LkO4JI5O MWPTRW5ITVJ?
DOHH-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvKTWM2OD1{Mz60OUBvVQ>? NEDPR5dUSU6JRWK=
IM-9 NYHOW2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M132eWlEPTB;MkOuOVQhdk1? M3ezfnNCVkeHUh?=
EC-GI-10 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrISZZUUUN3ME2yOE4zOyCwTR?= MmnCV2FPT0WU
HDLM-2 NHvPcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHniOIJKSzVyPUK0MlU1KG6P M4rsUHNCVkeHUh?=
LS-1034 NIXodYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf6V21KSzVyPUK1Mlc2KG6P MYDTRW5ITVJ?
REH MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zVOGlEPTB;Mk[uOFEhdk1? NYG3ZohIW0GQR1XS
LU-165 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrZTWlKSzVyPUK2MlczKG6P NWLBNHpRW0GQR1XS
NH-12 NVzFUXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIThOnlKSzVyPUK3MlY4KG6P NVHt[4M5W0GQR1XS
WSU-NHL NVHkXotZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvsTWM2OD1{OD6zPUBvVQ>? MnHYV2FPT0WU
ECC4 NITrXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1njbWlEPTB;MkiuO|khdk1? MlfUV2FPT0WU
OCI-AML2 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ7Lk[5JI5O M4X2N3NCVkeHUh?=
EW-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPMTGpKSzVyPUOwMlU6KG6P M4TaRXNCVkeHUh?=
NCI-H526 M{iwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfuXmZwUUN3ME2zNk42PCCwTR?= NXTUfld[W0GQR1XS
NCI-H719 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN2LkOxJI5O Mn3JV2FPT0WU
KARPAS-422 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K3UGlEPTB;M{WuNFQhdk1? MUHTRW5ITVJ?
SK-MEL-1 NVm3e3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zvV2lEPTB;M{WuNVchdk1? NFmxOpVUSU6JRWK=
ES3 M33xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3VZFrUUN3ME2zOU4yQSCwTR?= MmHGV2FPT0WU
UACC-812 NXfofoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP0TWM2OD1|NT60OEBvVQ>? NHzVRXFUSU6JRWK=
C8166 NHHaVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HUTmlEPTB;M{WuO{BvVQ>? MYTTRW5ITVJ?
MDA-MB-134-VI NYrzO|dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HHUmlEPTB;M{WuPFchdk1? MoTSV2FPT0WU
D-283MED NGi3U2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X0bGlEPTB;M{euO|khdk1? MkfSV2FPT0WU
SHP-77 M2nOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rWdGlEPTB;M{iuNFMhdk1? M4D5Z3NCVkeHUh?=
NCI-H2227 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkO2ZKSzVyPUSwMlQ6KG6P NELNWm9USU6JRWK=
SKM-1 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\VTWM2OD12Mj62N{BvVQ>? NUTqN3FtW0GQR1XS
L-428 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ocWlEPTB;NEOuPFYhdk1? M{\h[XNCVkeHUh?=
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR3Lki5JI5O NGXWb4FUSU6JRWK=
NCI-H716 M4HQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR6LkixJI5O NED5c4hUSU6JRWK=
DMS-79 NXyxWplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrTenpKSzVyPUWwMlcyKG6P M1HHSnNCVkeHUh?=
RS4-11 NUnjPYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDWSWhKSzVyPUWwMlg5KG6P M1TG[XNCVkeHUh?=
NCI-H720 NVr1WYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPvTZBrUUN3ME21NU4yOSCwTR?= NIe0UVdUSU6JRWK=
MC-CAR NVzJPXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTVzLkWyJI5O NFL5XIRUSU6JRWK=
TALL-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XkeGlEPTB;NUOuPVEhdk1? MX7TRW5ITVJ?
NCI-N87 NFnqUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD13ND6xPEBvVQ>? NWX6blV2W0GQR1XS
P30-OHK MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\PTWM2OD13ND62NUBvVQ>? M1L3e3NCVkeHUh?=
LP-1 M{XWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTjO41KSzVyPU[xMlI5KG6P NWXMU|g5W0GQR1XS
YT MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3dJpKSzVyPU[xMlghdk1? MXzTRW5ITVJ?
MRK-nu-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTZzLkiyJI5O NXvDcFNPW0GQR1XS
BT-474 M4\DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVezUIkzUUN3ME22OUBvVQ>? Mn3aV2FPT0WU
NCI-H322M Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLXTWM2OD14Nj6xNUBvVQ>? M37Q[HNCVkeHUh?=
NCI-H128 M3WweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmxfGxKSzVyPUe0Mlc4KG6P NVTzNIY6W0GQR1XS
KMS-12-PE NH;MOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfUNmtKSzVyPUe2MlI1KG6P MWjTRW5ITVJ?
KP-N-YS Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ziU2lEPTB;N{[uO|Qhdk1? NFPzc3pUSU6JRWK=
ALL-PO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILFRnhKSzVyPUe3MlY3KG6P M{[zNnNCVkeHUh?=
EW-13 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTd5Lke2JI5O MoTuV2FPT0WU
EW-11 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjhUIZqUUN3ME23PE42OiCwTR?= NGnzOHlUSU6JRWK=
SK-N-FI NHTkWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7VOXlsUUN3ME24NE4zKG6P MYfTRW5ITVJ?
CAL-148 M{D4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNfmlGUUN3ME24NU45PCCwTR?= MofmV2FPT0WU
RL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jjbGlEPTB;OE[uNFkhdk1? MoLCV2FPT0WU
AM-38 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zqWmlEPTB;OEiuNFghdk1? NXTPNJd2W0GQR1XS
RH-1 M33Md2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBc2lEPTB;OUmuPFUhdk1? MXTTRW5ITVJ?
NCI-H1770 NVjMe|RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFyMj60PUBvVQ>? MVzTRW5ITVJ?
SIG-M5 NG\POZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXzRXVKSzVyPUGwOU4xPiCwTR?= NVXsdVBxW0GQR1XS
GR-ST MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TlRWlEPTB;MUGzMlM1KG6P NFHkbnFUSU6JRWK=
ST486 NUTB[HpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknETWM2OD1zMUSuNFYhdk1? M2riW3NCVkeHUh?=
NCI-H1650 NFP3Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO5TWM2OD1zMUWuNlkhdk1? NYTjWlE2W0GQR1XS
MHH-CALL-2 M2D3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xlb2lEPTB;MUG1Mlchdk1? NUP0bIF2W0GQR1XS
BV-173 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HlRWlEPTB;MUKyMlcyKG6P MYrTRW5ITVJ?
MC116 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\4bng4UUN3ME2xOFgvQDVibl2= NFuze4hUSU6JRWK=
NCI-H524 NF7VUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqyZoxFUUN3ME2xOVkvOSCwTR?= M3[wbXNCVkeHUh?=
SCLC-21H MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCzT5VKSzVyPUG1PU41OSCwTR?= MXvTRW5ITVJ?
NCI-H1304 NXHGXW1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrIe4RKSzVyPUG2PU4zOSCwTR?= M{jMXnNCVkeHUh?=
NCI-H510A NF7PNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi2WHpnUUN3ME2xPFUvOzdibl2= MkDrV2FPT0WU
NCI-H209 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfGdZBMUUN3ME2xPVYvPTJibl2= Mke5V2FPT0WU
KM-H2 M{TZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;KW2lEPTB;MUm3MlA2KG6P M4jzV3NCVkeHUh?=
NCI-H1395 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzMD6xN{BvVQ>? MUPTRW5ITVJ?
NCI-H1155 M2LHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;JPGlEPTB;MkOwMlMzKG6P MoLtV2FPT0WU
COR-L279 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe0ZXFxUUN3ME2yOVIvOTdibl2= MV3TRW5ITVJ?
NCI-H1299 NXPPNZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD1{NkGuO|Ehdk1? M1r1e3NCVkeHUh?=
EW-22 NV;Ic3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ4Mz63OUBvVQ>? MV\TRW5ITVJ?
SK-MEL-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u2SGlEPTB;MkixMlkhdk1? NV\JZXRbW0GQR1XS
KASUMI-1 NY\OdGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW3eHpTUUN3ME2yPFMvODVibl2= M3vXbHNCVkeHUh?=
NCI-H187 NETTTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;CTmlEPTB;Mki3MlA5KG6P M{LGfnNCVkeHUh?=
NCI-H2171 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXWYJKSzVyPUK4PE46OiCwTR?= NVy3RWlHW0GQR1XS
LNCaP-Clone-FGC M2m4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ7NT6yOkBvVQ>? MnPLV2FPT0WU
NCI-H1522 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnwU5BKSzVyPUOwO{4xPSCwTR?= NW\Ke25UW0GQR1XS
SCH NHLhXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjRT5NzUUN3ME2zNlIvOjJibl2= M1frcXNCVkeHUh?=
THP-1 NEfMSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TjemlEPTB;M{KyMlYhdk1? MnvTV2FPT0WU
SNU-C1 NWrWdJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN4Mj6wPUBvVQ>? M2jsN3NCVkeHUh?=
CA46 NEj2b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN5Mz62N{BvVQ>? MVHTRW5ITVJ?
NCI-H1963 NYrEfGFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITWfXBKSzVyPUO4Ok4yQSCwTR?= Mlu4V2FPT0WU
DEL NFXrXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS3TWM2OD1|OUGuNlchdk1? MXLTRW5ITVJ?
TUR M1rzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITrWnJKSzVyPUO5Ok43OSCwTR?= NWPpS3R7W0GQR1XS
NCI-H226 M4jlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTRyMz6yN{BvVQ>? NEfCWoFUSU6JRWK=
COLO-668 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7XOHBKSzVyPUSwN{42PyCwTR?= MX\TRW5ITVJ?
CPC-N Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jOPGlEPTB;NECzMlc4KG6P M3[5R3NCVkeHUh?=
NCI-H889 NYDLcW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTiTWM2OD12NkGuPVIhdk1? MUnTRW5ITVJ?
J-RT3-T3-5 NVHXflV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTV|Mj61O{BvVQ>? M1zEfHNCVkeHUh?=
MSTO-211H M1zmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PWS2lEPTB;NUe0MlI3KG6P M4m3RXNCVkeHUh?=
SCC-15 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZ4Nz60O{BvVQ>? NIjuRm1USU6JRWK=
SUP-T1 NXe2UZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vcWlEPTB;Nki2MlA1KG6P MUfTRW5ITVJ?
DMS-153 M3zmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDSTWM2OD15NE[uPFMhdk1? M3WwUHNCVkeHUh?=
MS-1 NW\pSnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDDPYZFUUN3ME23OVkvPDJibl2= NUHqVnRyW0GQR1XS
TC-YIK M3fkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nJUWlEPTB;N{ixMlAyKG6P NV63[ZpPW0GQR1XS
RPMI-8866 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nIdGlEPTB;MUCwOk4zQCEQvF2= NEXhfppUSU6JRWK=
KY821 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDBVYtZUUN3ME2xNFM3NjB2IN88US=> MV;TRW5ITVJ?
P31-FUJ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzwTWM2OD1zMUGyMlc2KM7:TR?= M1\hUXNCVkeHUh?=
COLO-824 M3HFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zzUmlEPTB;MUK2NU44QCEQvF2= NH7TUYtUSU6JRWK=
U-698-M NX\0[lRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\IVJV3UUN3ME2yNlYzNjF3IN88US=> MVXTRW5ITVJ?
TE-441-T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzMTWM2OD1{NUKxMlch|ryP NIfCdGhUSU6JRWK=
IMR-5 NXvReXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv5TWM2OD1|NEC5MlYzKM7:TR?= MmnxV2FPT0WU
NCI-H1838 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiwdVdKSzVyPUSxPFYvOzJizszN M3K2OXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

プロトコル(参考用のみ)

キナーゼアッセイ:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞アッセイ:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物実験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome信号経路図

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID